AHA GUIDELINES Bundle (free trial)

High Blood Pressure - Merck Supported

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1539869

Contents of this Issue

Navigation

Page 57 of 87

58 Blood Pressure Management 5.2.7. Blood Pressure Goal for Patients With Hypertension COR LOE Recommendations 1 A 1. In adults with confirmed hypertension who are at increased risk* for CVD, an SBP goal of at least <130 mm Hg, with encouragement to achieve SBP <120 mm Hg, is recommended to reduce the risk of cardiovascular events and total mortality. 2b B-NR 2. In adults with confirmed hypertension who are not at increased risk* for CVD, an SBP goal of <130 mm Hg, with encouragement to achieve SBP <120 mm Hg, may be reasonable to reduce risk of further elevation of BP. 1 B-R 3. In adults with confirmed hypertension who are at increased risk* for CVD, a DBP target of <80 mm Hg is recommended to reduce the risk of cardiovascular events and total mortality. 2b B-NR 4. In adults with confirmed hypertension who are not at increased risk* for CVD, a DBP target of <80 mm Hg may be reasonable to reduce the risk of cardiovascular events. * Increased risk is defined as a 10-year predicted risk for CVD events of ≥7.5% using PREVENT. 5.3.1. Diabetes COR LOE Recommendations 1 A 1. In adults with T2D and hypertension, antihypertensive drug treatment should be initiated at an SBP of ≥130 mm Hg with a treatment goal of <130 mm Hg, with encouragement to achieve an SBP <120 mm Hg to reduce CVD morbidity and mortality. 1 C-LD 2. In adults with T2D and hypertension, antihypertensive drug treatment should be initiated at a DBP of ≥80 mm Hg with a treatment goal of <80 mm Hg to reduce CVD morbidity and mortality. 1 A 3. In adults with T2D and hypertension, all first-line classes of antihypertensive agents (ie, thiazide-type diuretics, long-acting CCB, ACEi, and ARB) are useful and effective for BP lowering. 1 A 4. In adults with diabetes and hypertension, ACEi or ARB are recommended in the presence of CKD as identified by eGFR <60 mL/min/1.73 m 2 or albuminuria ≥30 mg/g and should be considered when mild albuminuria (<30 mg/g ) is present to delay progression of diabetes-related kidney disease. 5.3. Comorbidities

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - High Blood Pressure - Merck Supported